Medulloblastoma - Pipeline Review, H2 2014

Date: July 31, 2014
Pages: 49
Price:
US$ 2,000.00 US$ 1,500.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MF7DB68C5DBEN
Leaflet:

Download PDF Leaflet

Summary

Global Markets Direct’s, ‘Medulloblastoma - Pipeline Review, H2 2014’, provides an overview of the Medulloblastoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Medulloblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medulloblastoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Medulloblastoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Medulloblastoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Medulloblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Medulloblastoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Medulloblastoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Medulloblastoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Medulloblastoma Overview
Therapeutics Development
Pipeline Products for Medulloblastoma - Overview
Pipeline Products for Medulloblastoma - Comparative Analysis
Medulloblastoma - Therapeutics under Development by Companies
Medulloblastoma - Therapeutics under Investigation by Universities/Institutes
Medulloblastoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Medulloblastoma - Products under Development by Companies
Medulloblastoma - Products under Investigation by Universities/Institutes
Medulloblastoma - Companies Involved in Therapeutics Development
Takeda Pharmaceutical Company Limited
Novartis AG
ThromboGenics NV
Stemline Therapeutics, Inc.
Conkwest, Inc.
Medulloblastoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
erismodegib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TPI-287 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TB-403 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SL-301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CST-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
siomycin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TBX-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Medulloblastoma - Recent Pipeline Updates
Medulloblastoma - Dormant Projects
Medulloblastoma - Product Development Milestones
Featured News & Press Releases
Feb 28, 2013: ThromboGenics And BioInvent Announce Publication Of Scientific Data On TB-403 In Journal Cell
Sep 19, 2011: Researchers Discover Regulatory Protein As Potential Drug Target For Brain Tumors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Medulloblastoma, H2 2014
Number of Products under Development for Medulloblastoma - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Medulloblastoma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014
Medulloblastoma - Pipeline by Novartis AG, H2 2014
Medulloblastoma - Pipeline by ThromboGenics NV, H2 2014
Medulloblastoma - Pipeline by Stemline Therapeutics, Inc., H2 2014
Medulloblastoma - Pipeline by Conkwest, Inc., H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Medulloblastoma Therapeutics - Recent Pipeline Updates, H2 2014
Medulloblastoma - Dormant Projects, H2 2014

LIST OF FIGURES

Number of Products under Development for Medulloblastoma, H2 2014
Number of Products under Development for Medulloblastoma - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Target, H2 2014
Number of Products by Stage and Top 10 Target, H2 2014
Number of Products by Top 10 Mechanism of Action, H2 2014
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
Number of Products by Top 10 Route of Administration, H2 2014
Number of Products by Stage and Top 10 Route of Administration, H2 2014
Number of Products by Top 10 Molecule Type, H2 2014
Number of Products by Stage and Top 10 Molecule Type, H2 2014

COMPANIES MENTIONED

Takeda Pharmaceutical Company Limited
Novartis AG
ThromboGenics NV
Stemline Therapeutics, Inc.
Conkwest, Inc.
Skip to top


Ask Your Question

Medulloblastoma - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: